Conformal High Dose Rate Brachytherapy Improves Biochemical Control And Cause Specific Survival in Patients With Prostate Cancer And Poor Prognostic Factors
- 1 March 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 169 (3) , 974-980
- https://doi.org/10.1097/01.ju.0000052720.62999.a9
Abstract
To improve outcome for patients with prostate cancer with poor prognostic factors higher than conventional radiation doses are required. To achieve this outcome a brachytherapy boost was given. We report the results of the first high dose rate dose-escalation brachytherapy trial. Between 1991 and 2000, 207 patients were prospectively enrolled in a dose escalation trial including pelvic radiotherapy and conformal high dose rate prostate brachytherapy boost. The dose was increased from 5.5 to 11.5 Gy. per implant. Patient eligibility for the study included pretreatment prostate specific antigen 10 or greater, Gleason 7 or greater or clinical stage T2b or higher. No patient received hormonal therapy. The American Society for Therapeutic Radiology and Oncology consensus panel definition of biochemical failure was applied. Median patient age was 69 years. Mean followup was 4.7 years (range 0.6 to 10.4). The 5-year actuarial biochemical control rate was 74%. The 5-year biochemical control was 85% for 1 poor prognostic factor, 75% for 2 and 50% for all 3 (p = 0.001). On Cox regression multivariate analysis lower brachytherapy dose, and higher Gleason and nadir value were associated with biochemical failure. The 5-year actuarial overall survival was 92%, cause specific survival 98% and disease-free survival 68%. The 5-year actuarial rates of complications were 8% and 0% for grades 3 and 4 genitourinary, and 0.5% and 0.5% for grades 3 and 4 gastrointestinal, respectively. The 5-year actuarial impotence rate was 51%. For patients with poor prognostic factors external beam radiation therapy with conformal high dose rate brachytherapy boost improved biochemical control, resulting in a high cause specific survival rate with low toxicity. Another important advantage is that the patient is not radioactive after the high dose rate implant.Keywords
This publication has 22 references indexed in Scilit:
- Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and GoserelinNew England Journal of Medicine, 1997
- Variation in prostate position quantitation and implications for three-dimensional conformal treatment planningInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥10 ng/mlInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer: Preliminary estimates of the therapeutic ratioInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Intraoperative optimization of needle placement and dwell times for conformal prostate brachytherapyInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons aloneInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Concurrent treatment planning for outpatient high dose rate prostate template implantsInternational Journal of Radiation Oncology*Biology*Physics, 1993
- Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancerUrology, 1993
- The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 1251 implantationInternational Journal of Radiation Oncology*Biology*Physics, 1991
- A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United StatesInternational Journal of Radiation Oncology*Biology*Physics, 1987